2025年12月17日,上海环码生物医药有限公司宣布,其自主研发的环形RNA药物——HM2002注射液,第三次获得国家药品监督管理局(NMPA)的临床试验许可(IND)。此次获批适应症为慢性冠脉综合征(Chronic Coronary Syndromes, CCS),并首次引入经导管心内膜注射的介入给药方式,标志着HM2002在缺血性心脏病领域完成了外科手术与介入干预双轨并进的临床开发布局。...
Efficient backsplicing produces translatable circular mRNAs.pdf
Extensive translation of circular RNAs driven by N6methyadenosine.pdf
Pervasive translation of circular RNAs driven by short IRES like elements.pdf
Study of circular RNA translation using reporter systems in living cells.pdf
Constructing GFP-based reporter to study back splicing and translation of circular RNA.pdf